> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# No ODAC Meeting for Margetuximab
- URL: https://www.fdaweb.com/no-odac-meeting-for-margetuximab/
- Published: 2020-05-28T12:00:00.000Z
- Updated: 2026-09-14T16:16:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146879

FDA has informed MacroGenics that it no longer plans to hold an Oncologic Drugs Advisory Committee meeting to discuss the company’s BLA for its margetuximab as a treatment for HER2-positive metastatic breast cancer. The agency also said it still expects to meet the 12/18 PDUFA goal date for application review.

The company [says](https://www.marketwatch.com/press-release/macrogenics-provides-update-on-fda-review-of-margetuximab-for-her2-positive-metastatic-breast-cancer-2020-05-28-71843945?tesla=y&ref=fdaweb.com) it is seeking approval of the investigational Fc-engineered monoclonal antibody that targets the HER2 oncoprotein for treating patients with pre-treated metastatic HER2-positive breast cancer in combination with chemotherapy.